VTGN 8-K 2026-09-25
Vistagen Therapeutics, Inc. (VTGN) 8-K dated 2026-09-25 — accession 0001628280-26-063510.
Vistagen Therapeutics, Inc. (VTGN) is a biotechnology company listed on NASDAQ.
Vistagen Therapeutics, Inc. filed a 8-K on 2026-09-25. Accession 0001628280-26-063510.
This 8-K covers: Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported VTGN revenue for 2026-03-31 was $1.3M. Net income was -$69.7M. Revenue was up 19.3% from 2024-03-31 to 2026-03-31. VTGN currently screens at market cap $28.1M.
Not investment advice. The VTGN SEC hub lists recent forms. The stock page is the research view.